Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

Study:

A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma

Rationale:

n/a

Purpose:

Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies

Study Status: Not yet recruiting

Recruiting:
n/a

Condition Intervention Phase
Asthma Drug: MEDI-563
Drug: MEDI-563
Drug: MEDI-563
Drug: MEDI-563
Other: Placebo
Phase 1

Verified by MedImmune LLC April, 2008

Sponsored by: MedImmune LLC
Information provided by: MedImmune LLC
ClinicalTrials.gov identifier: NCT00659659

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic, Lerner Research Institute
Cleveland, Ohio 44195
United States

Nestor Molfino, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site